Skip to main content

5 Top Stock Gainers for Monday: Aspen, SoFi, Flexion Therapeutics

Aspen Technology, Sofi Technologies, Flexion Therapeutics, Adamas Pharmaceuticals and Ocular Therapeutix are five top stock gainers for Monday.
  • Author:
  • Publish date:

Stocks ended lower Monday as investors prepped for a key week on Wall Street that could define market direction into the final months of the year.

Here are some of the market's biggest gainers for Monday:

1. Aspen Technology | Increase 12%

Aspen Technology  (AZPN) - Get Free Report shares jumped after Emerson Electric  (EMR) - Get Free Report announced plans for an $11 billion merger with the asset optimization software company that they said will accelerate their combined growth in the industrial software sector. Aspen shareholders will get $87 in cash, as well as 0.42 shares of the combined company.

2. Sofi Technologies | Increase 13%

Shares of Sofi Technologies  (SOFI) - Get Free Report climbed after Morgan Stanley analyst Betsy Graseck initiated coverage of the online financial services company with an overweight rating and $25 price target. She called SoFi a "powerful revenue growth story" as it ramps up its share of the consumer financial services wallet.

3. Flexion Therapeutics | Increase 58%

Flexion Therapeutics  (FLXN) - Get Free Report shares skyrocketed after Tampa, Fla.-based Pacira BioSciences said it is acquiring the biopharma company for $8 a share in cash, plus a non-tradeable contingent value right worth up to $8.50 a share in cash, in a deal aimed at expanding its position in non-opioid pain management. 

4. Adamas Pharmaceuticals | Increase 75%

Shares of Adamas Pharmaceuticals  (ADMS) - Get Free Report soared after Supernus Pharmaceuticals said it would acquire the drugmaker for about $400 million. Adamas Pharma shareholders will receive an upfront cash payment of $8.10 per share. The deal is expected to close in the fourth quarter or the first quarter of 2022.

5. Ocular Therapeutix | Increase 15%

Ocular Therapeutix  (OCUL) - Get Free Report shares surged after a posting on the U.S. Food and Drug Administration website indicated approval for the company's supplemental new drug application Dextenza, as a treatment for ocular itching linked to allergic conjunctivitis. Dextenza has already been approved as a treatment for ocular inflammation and pain following ophthalmic surgery.